Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 4/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13722312 | 0.86 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2D6CYP3A4TSHR | |
| SCHEMBL25810288 | 0.84 | ALDH1A1 (0.55) | ALDH1A1CYP1A2CYP2D6CYP3A4TSHR | |
| SCHEMBL8402970 | 0.83 | ALDH1A1 (0.51) | ALDH1A1CYP1A2CYP2D6CYP3A4TSHR | |
| SCHEMBL14010813 | 0.83 | — | — | |
| SCHEMBL25093262 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2D6CYP3A4TSHR | |
| SCHEMBL24341884 | 0.81 | ALDH1A1 (0.53) | ALDH1A1CYP1A2CYP2D6CYP3A4TSHR | |
| SCHEMBL14516281 | 0.81 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CYP3A4USP2HSD17B10 | |
| SCHEMBL29341868 | 0.80 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2D6CYP3A4TSHR | |
| SCHEMBL944668 | 0.79 | ALDH1A1 (0.53) | ALDH1A1CYP1A2TSHRHPGDSMN1; SMN2 | |
| SCHEMBL11406691 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889831-B2 | Unit dosage forms of pharmaceutical compositions comprising a polymer-factor VIII polypeptide conjugate | NEKTAR THERAPEUTICS (US) | 2014-11-18 | — | — | US | disclosed |
| US-8586711-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS (US) | 2013-11-19 | — | — | US | disclosed |
| US-8293869-B2 | Polymer conjugates of GLP-1 | NEKTAR THERAPEUTICS (US) | 2012-10-23 | — | — | US | disclosed |
| US-8247536-B2 | Factor VIII compositions | NEKTAR THERAPEUTICS (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120178692-A1 | DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-07-12 | — | — | US | disclosed |
| US-8143378-B2 | Polymer factor VIII moiety conjugates | NEKTAR THERAPEUTICS (US) | 2012-03-27 | — | — | US | disclosed |
| US-8133977-B2 | Polymer-factor VIII moiety conjugates | NEKTAR THERAPEUTICS (US) | 2012-03-13 | — | — | US | disclosed |
| US-7863421-B2 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS (US) | 2011-01-04 | — | — | US | disclosed |
| US-7858749-B2 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100249033-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100130684-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
| US-7199223-B2 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | F13B, F8, F13A1 | ALDH1A1 3597/4885CYP1A2 4487/4885CYP2D6 4200/4885 |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | ALDH1A1 2770/4885CYP1A2 1712/4885CYP2D6 1204/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | ALDH1A1 2876/4885CYP1A2 3352/4885CYP2D6 2880/4885 |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | ALDH1A1 2770/4885CYP1A2 1712/4885CYP2D6 1204/4885 |
| US-20100130684-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | ALDH1A1 3118/4885CYP1A2 3371/4885CYP2D6 2830/4885 |
| US-20120178692-A1 | DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | ALDH1A1 2188/4885CYP1A2 653/4885CYP2D6 248/4885 |
| US-20100249033-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | ALDH1A1 3118/4885CYP1A2 3371/4885CYP2D6 2830/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | ALDH1A1 2393/4885CYP1A2 1486/4885CYP2D6 1590/4885 |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | ALDH1A1 3118/4885CYP1A2 3371/4885CYP2D6 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.